News:
Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer's drug flops - Stocks making the biggest moves midday: Wynn Resorts, Rocket Lab USA, Cassava Sciences and more - Cassava Sciences Adviser Indicted on Fraud Charges
Cassava Sciences
Bookmark
ShareKey facts
- city: Austin
- state: TX
- country: United States
- sector: Health Care
- industry: Biotechnology
- CEO: Remi Barbier
- CEO gender: Male
Classified as: organization
Summary
Cassava Sciences is a company. It is located in Austin, the United States. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business
Cassava Sciences is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 266.8M $
- Debt: 213K $
- Employees: 24 people
- Free cash flow: -56070500 $
- Market cap: 1.3B $
- Revenues:
get
Premium to see estimate
Stocks from Cassava Sciences
Explore more on business
Talking Points:
- Cassava Sciences, Inc.
- The Investor Relations website contains information about Cassava Sciences, Inc.'s business for stockholders, potential investors, and financial analysts.
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Learn more about talking points